SG11201806623VA - Bacteria over-expressing c-di-amp and therapeutic methods - Google Patents
Bacteria over-expressing c-di-amp and therapeutic methodsInfo
- Publication number
- SG11201806623VA SG11201806623VA SG11201806623VA SG11201806623VA SG11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- maryland
- baltimore
- mycobacterium
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/130616 Al 18 August 2016 (18.08.2016) WIPO I PCT 11111111111111 0 11101 010 11111 0111 11111 01110111 01111101E11011 111111111111111 0111111 (51) International Patent Classification: A61K 39/04 (2006.01) A61K 48/00 (2006.01) A61K 35/74 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2016/017248 (22) International Filing Date: 10 February 2016 (10.02.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/114,610 11 February 2015 (11.02.2015) US (71) Applicant: THE JOHNS HOPKINS UNIVERSITY [US/US]; 3400 N. Charles Street, Baltimore, Maryland 21218 (US). (72) Inventors: BISHAI, William R.; 1202 Ridervale Road, Baltimore, Maryland 21204 (US). DEY, Ruchi Jain; 6316 Greenspring Ave., Apt. 208, Baltimore, Maryland 21209 (US). DEY, Bappaditya; 6316 Greenspring Ave., Apt. 208, Baltimore, Maryland 21209 (US). (74) Agent: FEULNER, Gregory; 100 N. Charles Street, 5th Floor, Baltimore, Maryland 21201 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) W O 20 16/ 1306 16 Al (54) Title: BACTERIA OVER-EXPRESSING C-DI-AMP AND THERAPEUTIC METHODS (57) : The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobac- terium bovis, or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a my - cobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.?
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562114610P | 2015-02-11 | 2015-02-11 | |
PCT/US2016/017248 WO2016130616A1 (en) | 2015-02-11 | 2016-02-10 | Bacteria over-expressing c-di-amp and therapeutic methods |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806623VA true SG11201806623VA (en) | 2018-09-27 |
Family
ID=56615726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806623VA SG11201806623VA (en) | 2015-02-11 | 2016-02-10 | Bacteria over-expressing c-di-amp and therapeutic methods |
Country Status (4)
Country | Link |
---|---|
US (3) | US10130663B2 (en) |
CA (1) | CA3013713A1 (en) |
SG (1) | SG11201806623VA (en) |
WO (1) | WO2016130616A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3013713A1 (en) * | 2015-02-11 | 2016-08-18 | The Johns Hopkins University | Bacteria over-expressing c-di-amp and therapeutic methods |
EP3402498A1 (en) | 2016-01-11 | 2018-11-21 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
BR112019013863A2 (en) * | 2017-01-06 | 2020-03-03 | Synlogic Operating Company, Inc. | MICRO-ORGANISMS PROGRAMMED TO PRODUCE IMMUNE AND ANTICANCER THERAPEUTIC MODULATORS IN TUMOR CELLS |
CN111246865A (en) * | 2017-07-12 | 2020-06-05 | 同生运营公司 | Microorganisms programmed to produce immunomodulators and anticancer therapeutics in tumor cells |
JP2021512144A (en) * | 2018-01-26 | 2021-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアThe Regents of the University of California | Intranasal delivery of tuberculosis vaccine containing cyclic dinucleotide adjuvant |
CN112601535A (en) * | 2018-04-17 | 2021-04-02 | 约翰霍普金斯大学 | Recombinant therapeutic intervention for cancer |
CA3194581A1 (en) * | 2020-10-01 | 2022-04-07 | Alok Singh | Bcg based vaccine compositions and methods of use thereof |
CN112342233B (en) * | 2020-11-10 | 2022-08-26 | 上海陶宇晟生物技术有限责任公司 | Polynucleotide for increasing c-di-AMP production when bacteria express DacA |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026819A2 (en) * | 2000-09-26 | 2002-04-04 | Roger Williams Hospital | Recombinant bcg vaccines for the prevention and treatment of cancer |
US9061048B2 (en) * | 2010-12-15 | 2015-06-23 | The Regents Of The University Of California | Cyclic di-AMP induction of type I interferon |
WO2013040548A2 (en) | 2011-09-17 | 2013-03-21 | Yale University | Fluoride-responsive riboswitchs, fluoride transporters, and methods of use |
WO2013066264A1 (en) | 2011-10-31 | 2013-05-10 | Nanyang Technological University | Enzymatic synthesis of cyclic and linear diadenosine monophosphate |
JP5650780B2 (en) | 2012-04-04 | 2015-01-07 | 日東電工株式会社 | Vaccine composition |
EP2858722B8 (en) * | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
BR112015013440B1 (en) | 2012-12-13 | 2020-12-08 | Aduro Biotech, Inc | compositions comprising cyclic purine dinucleotides with stereochemistry |
JP6512567B2 (en) | 2013-02-05 | 2019-05-15 | 日東電工株式会社 | WT1 peptide cancer vaccine composition for transdermal administration |
US10076491B2 (en) | 2013-02-05 | 2018-09-18 | Nitto Denko Corporation | Vaccine composition |
CA2840978A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for mucosal administration |
JP6497691B2 (en) | 2013-02-05 | 2019-04-10 | 日東電工株式会社 | WT1 peptide cancer vaccine composition for mucosal administration |
JP6453855B2 (en) | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック,インク. | Compositions and methods for activating "interferon gene stimulator" dependent signaling |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
CA3013713A1 (en) * | 2015-02-11 | 2016-08-18 | The Johns Hopkins University | Bacteria over-expressing c-di-amp and therapeutic methods |
DK3317301T3 (en) | 2015-07-29 | 2021-06-28 | Immutep Sas | COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3 |
CN105367617A (en) | 2015-09-25 | 2016-03-02 | 武汉品生科技有限公司 | Derivative based on c-di-AMP, tat polypeptide and application of derivative in inhibitor in type I interferon micromolecules |
BR112018008339A2 (en) | 2015-10-28 | 2018-10-30 | Aduro Biotech Inc | compositions and methods for activating interferon gene-dependent signaling enhancer |
CN106554416B (en) | 2015-12-09 | 2019-03-15 | 聊城市奥润生物医药科技有限公司 | A kind of application of anti-PD-L1 Humanized monoclonal antibodies joint interferon gene stimulates the protein (STING) agonist in antitumor |
CN106539814A (en) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | Interferon gene stimulatory protein(SP)(STING)Application of the agonist in the diseases such as resisting rheumatoid arthritis |
WO2017106740A1 (en) | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production |
EP3448397A4 (en) | 2016-04-26 | 2020-01-08 | Qu Biologics Inc. | Therapeutically triggering an innate immune response in a target tissue |
CN106539816A (en) | 2016-04-30 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | Application of the ring dinucleotides in preventing and treating multiple sclerosis |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
WO2018026717A1 (en) | 2016-08-01 | 2018-02-08 | Aduro Biotech, Inc. | Protein expression enhancer sequences and use thereof |
WO2018030457A1 (en) | 2016-08-10 | 2018-02-15 | 武田薬品工業株式会社 | Method for modifying target site in genome of eukaryotic cell, and method for detecting presence or absence of nucleic acid sequence to be detected at target site |
CN112601535A (en) * | 2018-04-17 | 2021-04-02 | 约翰霍普金斯大学 | Recombinant therapeutic intervention for cancer |
-
2016
- 2016-02-10 CA CA3013713A patent/CA3013713A1/en active Pending
- 2016-02-10 WO PCT/US2016/017248 patent/WO2016130616A1/en active Application Filing
- 2016-02-10 SG SG11201806623VA patent/SG11201806623VA/en unknown
- 2016-02-10 US US15/550,434 patent/US10130663B2/en active Active
-
2018
- 2018-10-01 US US16/147,916 patent/US10842828B2/en active Active
-
2020
- 2020-11-19 US US16/953,162 patent/US11590177B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10130663B2 (en) | 2018-11-20 |
US20190030091A1 (en) | 2019-01-31 |
CA3013713A1 (en) | 2016-08-18 |
US20180028577A1 (en) | 2018-02-01 |
US10842828B2 (en) | 2020-11-24 |
US11590177B2 (en) | 2023-02-28 |
US20210145896A1 (en) | 2021-05-20 |
WO2016130616A1 (en) | 2016-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806623VA (en) | Bacteria over-expressing c-di-amp and therapeutic methods | |
SG11201803906PA (en) | Control of cellular redox levels | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201900269XA (en) | Channel sensing for independent links | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201807573VA (en) | Methods for providing single-stranded rna | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201810179RA (en) | Novel crispr enzymes and systems | |
SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201809341PA (en) | Mobile robot | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
SG11201810196RA (en) | Cancer treatments |